STOCK TITAN

PMV Pharmaceuticals (PMVP) director gifts 84K stock options to trust

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PMV Pharmaceuticals director Carol Giltner Gallagher reported option grants and internal transfers involving 42,000-share stock options. She received a stock option for 42,000 shares of common stock at an exercise price of $1.19 per share, expiring on June 4, 2036.

According to a footnote, these options vest on the earlier of June 4, 2027 or the issuer’s next annual meeting of stockholders. The filing also shows bona fide gifts moving options covering a total of 84,000 underlying shares, including a transfer to The Gallagher Revocable Trust dated May 10, 2011, for which she serves as trustee. These are non-market, gift and grant transactions rather than open-market buys or sells.

Positive

  • None.

Negative

  • None.
Insider Gallagher Carol Giltner
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 42,000 $0.00 --
Gift Stock Option (right to buy) 42,000 $0.00 --
Gift Stock Option (right to buy) 42,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 42,000 shares (Direct, null); Stock Option (right to buy) — 42,000 shares (Indirect, See footnote)
Footnotes (1)
  1. Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee.
Option grant size 42,000 shares Stock option covering common stock granted on June 4, 2026
Gifted option shares 84,000 shares Total underlying shares in bona fide gift transactions
Exercise price $1.19 per share Conversion or exercise price of the stock options
Expiration date June 4, 2036 Option expiration for all reported stock option entries
Vesting trigger date June 4, 2027 Options vest on this date or on next annual meeting date
Gift transaction count 2 transactions Number of bona fide gift entries in transaction summary
Net buy/sell direction neutral Transaction summary shows no net open-market buying or selling
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
bona fide gift financial
"transaction_code_description: Bona fide gift"
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
conversion or exercise price financial
"conversion_or_exercise_price: 1.1900"
Revocable Trust financial
"held of record by The Gallagher Revocable Trust dated May 10, 2011"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
vest financial
"Shares subject to the option vest on the earlier of June 4, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gallagher Carol Giltner

(Last)(First)(Middle)
C/O PMV PHARMACEUTICALS, INC.
400 ALEXANDER PARK DRIVE, SUITE 301

(Street)
PRINCETON NEW JERSEY 08540

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PMV Pharmaceuticals, Inc. [ PMVP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$1.1906/04/2026A42,000 (1)06/04/2036Common Stock42,000$042,000D
Stock Option (right to buy)$1.1906/04/2026G42,000 (1)06/04/2036Common Stock42,000$00D
Stock Option (right to buy)$1.1906/04/2026G42,000 (1)06/04/2036Common Stock42,000$042,000ISee footnote(2)
Explanation of Responses:
1. Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.
2. The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee.
/s/ Robert Ticktin, by power of attorney06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did PMV Pharmaceuticals (PMVP) report for Carol Giltner Gallagher?

The filing shows Carol Giltner Gallagher received a stock option grant for 42,000 PMV Pharmaceuticals shares and reported bona fide gift transfers involving options over 84,000 underlying shares. These are non-market gifts and grants, not open-market purchases or sales.

What are the key terms of Carol Giltner Gallagher’s 42,000 PMVP stock option?

The option covers 42,000 shares of PMV Pharmaceuticals common stock at an exercise price of $1.19 per share and expires June 4, 2036. It vests on June 4, 2027 or on the date of the issuer’s next annual stockholder meeting, whichever occurs first.

Were PMV Pharmaceuticals (PMVP) shares bought or sold on the market in this Form 4?

No open-market trades occurred in this Form 4. The reported transactions are a stock option grant and bona fide gifts of options, which move rights between the director and a revocable trust but do not represent market purchases or sales of PMVP shares.

How many PMV Pharmaceuticals option shares were transferred by gift in this filing?

The transaction summary shows bona fide gifts involving options over 84,000 underlying PMV Pharmaceuticals common shares. These gifts include transferring options from direct ownership to The Gallagher Revocable Trust, a revocable trust where the reporting person serves as trustee, changing the holding structure.

What is The Gallagher Revocable Trust’s role in the PMV Pharmaceuticals (PMVP) Form 4?

A footnote states that certain securities are held of record by The Gallagher Revocable Trust dated May 10, 2011, for which the reporting person serves as trustee. Some option interests are gifted to this trust, shifting record ownership while keeping the director involved as trustee.

When do Carol Giltner Gallagher’s PMV Pharmaceuticals options begin to vest?

The options vest on the earlier of June 4, 2027 or the date of PMV Pharmaceuticals’ next annual meeting of stockholders. This schedule ties vesting either to a fixed future date or to the timing of the company’s upcoming annual shareholder meeting, whichever arrives first.